![]() |
市場調査レポート
商品コード
1439903
デジタル吸入器 - 世界市場の考察、競合情勢、市場予測(2030年)Digital Dose Inhalers - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
||||||
カスタマイズ可能
適宜更新あり
|
デジタル吸入器 - 世界市場の考察、競合情勢、市場予測(2030年) |
出版日: 2024年02月01日
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2~10営業日
|
世界のデジタル吸入器の市場規模は、2024年~2030年の予測期間にCAGRで11.27%の成長が見込まれます。市場は、喘息、慢性閉塞性肺疾患(COPD)、嚢胞性線維症、喘息COPDオーバーラップ症候群などの呼吸器疾患の有病率の上昇などの要因により、大幅な市場成長を示しています。さらに、主要製薬企業によるデジタル技術の採用の急増、大気汚染の増加、喫煙者の増加、粉塵、煙、空気中の粒子への曝露の増加が、デジタル吸入器市場を後押しします。さらに、近年の製品の発売や規制当局の承認などの技術の進歩は、予測期間(2024年~2030年)にデジタル吸入器市場全体を牽引すると予測されます。したがって、市場は2024年~2030年の予測期間に大幅なCAGRで成長すると推定されます。
デジタル吸入器の市場力学
デジタル吸入器市場を牽引する重要な特徴の1つは、さまざまな呼吸器疾患の世界の有病率の上昇です。
例えば、世界保健機関(WHO)(2022)のデータによると、喘息は2019年に約2億6,200万人近くが罹患し、同年に世界全体で4億5,500万人の死亡を引き起こしました。
また、Global Burden of Disease Study(2019)のデータによると、COPDの有病者数は世界で2億1,230万人と報告されており、2019年の1年間で330万人が死亡しています。喘息とCOPDに加えて、嚢胞性線維症の件数も常に伸びています。March of Dimes Organization(2019)のデータによると、2019年に世界で約7万人~10万人が嚢胞性線維症に罹患しており、男性も女性も同じ割合で罹患しています。
さらに、大気汚染の増加も、今後数年間におけるデジタル吸入器の需要を促進すると予測されています。例えば、Organization for Economic Co-operation and Development(2022)によると、2050年までに世界の温室効果ガス(GHG)の排出は約50%増加すると予測されており、これは主にエネルギー関連のCO2排出が70%増加するためです。また、GHGの大気中濃度は2050年までにCO2換算で685ppmに達する可能性があり、その結果、今世紀末には世界の平均気温が産業革命前のレベルを3~6度上回ることになるとしています。
上記の要因とともに、技術開発は絶えず増加しており、デジタル吸入器市場の成長を後押ししています。例えば、ドラッグデリバリーシステム、サービス、アクティブマテリアルサイエンスソリューションのグローバルリーダーであるAptar Pharmaは、2022年2月に、標準的な定量噴霧式吸入器(pMDI)をスマートコネクテッド医療機器に変換する革新的なデジタル呼吸器ヘルスソリューションであるHeroTracker® Senseの発売を発表しました。
したがって、上記の要因が2024年~2030年の予測期間にデジタル吸入器市場全体を牽引します。
しかし、機器の高いコストやデジタルデータの正確性に関する懸念などが、デジタル吸入器市場の成長にとっての課題となる可能性があります。
COVID-19パンデミックは、デジタル吸入器市場の製造、供給、輸出入、その他の関連活動の混乱につながるロックダウン、国境閉鎖などにより、最初の数ヶ月間、デジタル吸入器の市場成長に若干マイナスの影響を与えました。また、COVID-19の原因物質であるSARS-CoV-2ウイルスの蔓延の恐れや、パンデミックにまつわる不確実性のために、世界中の多くの国が、緊急時を除いて肺機能検査(PFT)室の閉鎖を余儀なくされました。しかし、中等度から重度の喘息やコントロールされていない喘息に苦しむ人々は、COVID-19によって入院する可能性が高かったです。またCOVID-19パンデミックはその後半において、世界中の人々の肺の健康に関する意識と懸念のために、デジタル吸入器の伸びにつながり、このことがさらに肺機能検査に用いるデジタルまたはスマート吸入器などの吸入器の利用を加速させ、デジタル吸入器の市場成長を促進しています。さらに、デジタル吸入器のeコマースの開始により、市場での需要が増加しました。このように、上記の要因に加え、高いワクチン接種率、政府によるロックダウンの緩和により、デジタル吸入器の需要は2022年~2028年の予測期間にデジタル吸入器市場全体を促進します。
当レポートでは、世界のデジタル吸入器市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。
DIGITAL DOSE INHALERS MARKET BY PRODUCT TYPE (DRY POWDER INHALERS AND METERED DOSE INHALERS), BY APPLICATION (CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ASTHMA, AND OTHERS), AND BY GEOGRAPHY IS EXPECTED TO ADVANCE AT A RESPECTABLE CAGR FORECAST till 2030 OWING TO THE ACCELERATING PREVALENCE OF RESPIRATORY DISORDERS SUCH AS ASTHMA, COPD, AND OTHERS, THE RISING AIR POLLUTION, AND THE GROWING NUMBER OF PRODUCT DEVELOPMENT ACTIVITIES SUCH AS PRODUCT LAUNCHES AND REGULATORY APPROVALS ACROSS THE GLOBE
The global digital dose inhalers market will grow at a CAGR of 11.27% during the forecast period from 2024 to 2030. The digital dose inhalers market is witnessing significant market growth due to the factors such as the rising prevalence of respiratory disorders such as asthma, chronic obstructive pulmonary disorder (COPD), cystic fibrosis, asthma-COPD overlap syndrome, and others. Furthermore, the surging adoption of digital technology by key pharmaceutical players, the rising air pollution, increase in the population of smokers, and increasing exposure to dust, fumes, and airborne particles will spur the market of digital dose inhalers. Additionally, the growing technological advancements such as recent product launches and regulatory approvals is expected to drive the overall market for digital dose inhalers during the forecast period (2024-2030). Therefore, the market for digital dose inhalers is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.
DIGITAL DOSE INHALERS MARKET DYNAMICS:
One of the key aspect for driving the digital dose inhalers market is the rising prevalence of various respiratory disorders globally.
For instance, as per data by the World Health Organization (WHO) 2022, asthma affected approximately nearly 262 million people in 2019, causing 455,000 deaths in the same year, globally.
Also, according to data by the Global Burden of Disease Study (2019), there were 212.3 million prevalent cases of COPD reported globally, accounting for 3.3 million deaths in the year 2019. In addition to asthma and COPD, the numbers for cystic fibrosis are constantly on the rise. As per data by the March of Dimes Organization (2019), about 70,000 to 100,000 people had cystic fibrosis in the year 2019 globally, affecting males and females at the same rate.
Moreover, the rising air pollution is also expected to drive the demand for digital dose inhalers in the upcoming years. For instance, as per the Organization for Economic Co-operation and Development 2022, by 2050 the emission of global greenhouse gases (GHGs) could be anticipated to increase by about 50%, majorly owing to 70% growth in energy-related CO2 emissions. It also stated that the atmospheric concentration of GHGs could reach 685 parts per million (ppm) CO2- equivalents by 2050, resulting in the global average temperatures to be 3 to 6 degree Celsius above the pre-industrial levels by the end of the century.
Along with the factors mentioned above, the number of technological developments are constantly increasing, bolstering the growth of the digital dose inhalers market. For instance, in February 2022, Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, announced the launch of HeroTracker® Sense, a novel digital respiratory health solution that transforms a standard metered dose inhaler (pMDI) into a smart connected healthcare device.
Therefore, the factors stated above collectively will drive the overall digital dose inhalers market during the forecast period from 2024-2030.
However, high cost of the devices, concerns regarding the accuracy of digital data, and others may prove to be challenging factors for digital dose inhalers market growth.
The COVID- 19 pandemic had a slightly negative impact on the market growth of digital dose inhalers during the initial few months owing to the lockdown impositions, border closures, and others leading to disruption in the manufacturing, supply, import, export, and other related activities of the digital dose inhalers market. Also, owing to the fear of spread of SARS-CoV-2 virus which is the causative agent for COVID-19 and uncertainties revolving around the pandemic, many countries across the world were forced to close down pulmonary function tests (PFT) laboratories except in case of emergencies. However, people suffering from moderate-to-severe or uncontrolled asthma were more likely to get hospitalized from COVID-19. The COVID -19 pandemic also led to rise in digital dose inhalers in the later half owing to the awareness and concerns regarding lung health among the people across the world which is further accelerated the utilization of respiratory inhalers such as digital or smart inhalers for the testing of lung function, driving the market growth for digital dose inhalers. Moreover, with the commencement of e-commerce availability of digital dose inhalers, increased its demand in the market. Thus, along with the above-mentioned factors, high vaccination rates and relaxations in the government-imposed lockdown, the demand for digital dose inhalers is subjected to increase driving the overall market for digital dose inhalers during the forecast period of 2022 - 2028.
DIGITAL DOSE INHALERS MARKET SEGMENT ANALYSIS:
Digital Dose Inhalers Market by Product Type (Dry Powder Inhalers and Metered Dose Inhalers), Application (Chronic Obstructive Pulmonary Disease, Asthma, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the product type segment of the digital dose inhalers market, the dry powder inhalers segment is expected to have a significant revenue share in the year 2023. This was primarily owing to the increasing prevalence of respiratory diseases, increasing technological advancements pertaining to the device, and surging launches by the key players in the market.
For instance, dry powder inhalers (DPI's) in general are easier to use than the metered dose inhalers (MDI) and cause fewer irritant effects.
Moreover, concerns related to the incidences of drug irritation caused by the presence of propellant components, such as chlorofluorocarbons (CFCs) in metered dose inhalers, have favored the adoption of the dry powder inhalers, with fewer irritant effects while delivering comparable therapeutic efficacy as metered dose inhalers. Thus, the dry powder inhalers are also known as propellant free inhalers.
Further, the DPI deposit the medicine in the lungs at a much higher rate than MDIs. This makes them more efficient and effective as they can provide a higher quantity of medicine with a single dose.
Additionally, the increasing product launches are also expected to contribute to the growth of the studied segment during the forecast period. For instance, in December 2020, Berry Global launched the RS01 single-dose dry powder inhaler with built-in sensors and digital capabilities. The RS01 tracks inhaler use and connects to a companion app that provides personalized guidance to improve adherence and inhaler technique.
Therefore, owing to the advantages associated with dry powder inhaler and increasing product launches, the category is expected to witness a considerable growth eventually contributing to the overall growth of the global digital dose inhalers market during the forecast period.
NORTH AMERICA IS EXPECTED TO DOMINATE THE OVERALL DIGITAL DOSE INHALERS MARKET:
Among all the regions, North America is expected to dominate the global digital dose inhalers market in the year 2023 and is expected to do the same during the forecast period from 2024-2030. This can be ascribed to the escalating prevalence of various respiratory disorders, increasing burden of geriatric population prone to respiratory disorder, and the presence of key market players in the region are another factors which acts as a supportive factor for the North America's digital dose inhalers market growth.
As per the data published by World Health Organization (WHO) 2022, approximately 25 million people in the United States had asthma in the year 2020 including 4.2 million children, which equals about 1 in every 13 people.
Moreover, according to the National Center for Health Statistics 2019-2020, stated that the percentage of COPD, emphysema, or chronic bronchitis for adults aged 18 and over, in the United States, increased from 4.6% in 2019 to 5.0% in 2020.
In other countries of North America such as Canada, the numbers for respiratory ailments are substantially increasing. According to statistics by the Lung Association 2020-2022, it was concluded that about 2.6 million Canadians were living with asthma in the year 2020 - 2022.
Thus, from the above sources and statistics it can be concluded that the respiratory disorders are increasing in the North America, ultimately increasing the demand of digital dose inhalers in the market.
Additionally, as per the New Mexico Department of Health Epidemiology and Response Division, 2019, in the year 2023, approximately 16.0% of adults were current smokers and nearly 32.7% of high school students were current smokers. The increasing consumption of smoking will increase the risk of developing respiratory disorders or lung cancer, ultimately increasing the demand of digital dose inhalers in order to treat and manage the respiratory disorders.
Furthermore, the increasing product launches, regulatory approvals, acquisitions, partnerships, and other activities by key players in the region will drive the market of digital dose inhalers in the upcoming years. For instance, in July 2020, Teva Pharmaceuticals, one of the prominent player in healthcare industries, announced the launch of its ProAir Digihaler in the United States. It is used in people >=4 years old to treat or prevent bronchospasm in people who have reversible obstructive airway disease or to prevent exercise-induced bronchospasm.
Henceforth, the interplay of the aforementioned factors above would provide a conducive growth environment for the North American region in the digital dose inhalers market.
DIGITAL DOSE INHALERS MARKET KEY PLAYERS:
Some of the key market players operating in the digital dose inhalers market includes Glenmark Pharmaceuticals, Novartis AG, ResMed, Koninklijke Philips N.V., Teva Pharmaceutical Industries Ltd., H&T Presspart Manufacturing Ltd., AptarGroup, Inc., Amiko Digital Health Limited., Trudell Medical UK Limited, BreatheSuite Inc., Opko Health, Inc., Cipla Inc., Sensirion AG, 3M, adherium, and others.
RECENT DEVELOPMENTAL ACTIVITIES IN DIGITAL DOSE INHALERS MARKET:
In February 2022 Astrazeneca and Honeywell partnered to develop next-generation respiratory inhalers using the propellant HFO-1234ze, which has up to 99.9% less global warming potential than propellants currently used in respiratory medicines.
In February 2019, Propeller Health, delivering one of the digital respiratory health platform, signed a partnership with Orion Corporation in order to bring the Propeller's products among European patients.
KEY TAKEAWAYS FROM THE DIGITAL DOSE INHALERS MARKET REPORT STUDY
TARGET AUDIENCE WHO CAN BE BENEFITED FROM THIS DIGITAL DOSE INHALERS MARKET REPORT STUDY
FREQUENTLY ASKED QUESTIONS FOR DIGITAL DOSE INHALERS MARKET:
The digital dose inhalers are devices that deliver a specific amount of medication to the lungs in the form of aerosolized medicine or dry powder. These inhalers have built-in sensors that detect use of inhaler and measure respiratory flow, according to the release and dose management.
The global digital dose inhalers market will grow at a CAGR of 11.27% during the forecast period from 2024 to 2030.
The digital dose inhalers market is witnessing a positive market growth owing to the factors such as increasing of prevalence of respiratory disorders such as asthma, chronic obstructive pulmonary disorder (COPD), cystic fibrosis, asthma-COPD overlap syndrome, and others. Further, the surge in the adoption of digital technology by key pharmaceutical players, rising air pollution, and increase in the population of smokers will aid in driving the market of digital dose inhalers. Also, the increasing product launches and regulatory approvals will create an exigency for the digital dose inhalers market.
Some of the key market players operating in the digital dose inhalers market includes Glenmark Pharmaceuticals, Novartis AG, ResMed, Koninklijke Philips N.V., Teva Pharmaceutical Industries Ltd., H&T Presspart Manufacturing Ltd., AptarGroup, Inc., Amiko Digital Health Limited., Trudell Medical UK Limited, BreatheSuite Inc., Opko Health, Inc., Cipla Inc., Sensirion AG, 3M, adherium, and others.
Among all the regions, North America is estimated to amass the significant revenue share in the global digital dose inhalers market. This can be ascribed to the escalating prevalence of various respiratory disorders, increasing burden of geriatric population prone to respiratory disorder, and the presence of key market players in the region are another factors which acts as a supportive factor for the North America's digital dose inhalers market growth.